Ironwood Pharmaceuticals (IRWD) PT Lowered to $17 at BTIG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
UPDATE: Credit Suisse Downgrades Ironwood Pharmaceuticals (IRWD) to Neutral
November 7, 2018 5:15 AM EST(Updated - November 7, 2018 7:56 AM EST)
(updated to add analyst comments)
Credit Suisse analyst Vamil Divan downgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Outperform to Neutral with a price target of $14.00 (from $22.00) citing disappointing updates on key product Linzess and what... More
JPMorgan Downgrades Ironwood Pharmaceuticals (IRWD) to Underweight
November 7, 2018 5:10 AM ESTJPMorgan analyst Eric Joseph downgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Neutral to Underweight with a price target of $11.00 (from $20.00).
For an analyst ratings summary and ratings history on Ironwood Pharmaceuticals click here. For more ratings news on Ironwood Pharmaceuticals click here.
Shares of Ironwood Pharmaceuticals closed at $12.78 yesterday.
... More